Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022

Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022




Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022

Shows potential for CD8+ T cell targeted immunotherapy for chronic viral infections

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders, today announced that it will present the first preclinical data for AB359, its CD8-targeted interleukin-2 (IL-2) immunotherapy for the treatment of chronic viral infections, at the American Association for the Study of Liver Disease (AASLD) 2022 Annual Meeting, being held in Washington, DC, on November 4-8, 2022. The preclinical data indicates that selective activation of the IL-2 pathway in CD8+ T cells drives antiviral activity in a model of hepatitis B virus (HBV) and supports the development of AB359 as a potentially more tolerable and more active IL‑2-based therapy for the treatment of chronic HBV.

Details of the poster presentation are as follows:

Title: Selective activation of the IL-2 pathway in CD8+ T cells drives antiviral activity in a hepatitis B virus (HBV) model

Session Date and Time: November 4, 2022, 12:00-1:00 p.m. ET

Location: Poster Hall
Abstract Number: 1198

About Asher Bio

Asher Bio is a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders. We utilize our proprietary cis-targeting platform to develop therapies engineered to overcome limitations of other immune-based treatments by selectively activating specific immune cell types with validated disease fighting functionality. Our candidates feature an antibody connected to a modified immunomodulatory protein, such as a cytokine. Our candidate design is intended to enable our candidates to selectively activate the desired immune cells and not other cells that contribute to toxicity or immune suppression. Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco. For more information, please visit www.asherbio.com and follow us on Twitter @AsherBio and on LinkedIn.

Contacts

Media Contact

Kathryn Morris, The Yates Network

914-204-6412

kathryn@theyatesnetwork.com

Investor Contact

Hannah Deresiewicz, Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com